Change of Lung Function After Exercise in Patients With Chronic Obstructive Pulmonary Disease

Quality of Life Clinical Trial

Official title:

Impact of Exercise on Lung Function in Patients With Chronic Obstructive Pulmonary Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03551197
• Other study ID #: 2018-HXNK-001
• Status: Recruiting
• Phase: Phase 4
• Start date: June 13, 2018
• Est. completion date: September 2018

Study information

• Verified date: May 2018
• Source: Zhujiang Hospital
• Contact: Huapeng Yu
• Phone: +86 020-61643888
• Email: 359606545[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the changes of lung function before and after the exercise in patients with chronic obstructive pulmonary disease.The assessment of quality of life is also carried out through questionnaires.

Description:

This is a randomized,open-label study to research the changes of lung function before and after exercise in patients with chronic obstructive pulmonary disease .At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),Clinical Chronic Obstructive Pulmonary Questionnaire(CCQ) and chronic obstructive pulmonary assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months` treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: September 2018
• Est. primary completion date: September 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Male or female patients 18 to 80 years-old, inclusive.

• A clinical diagnosis of chronic obstructive pulmonary disease according to the Global Initiative for Chronic Obstructive Disease(GOLD 2018) guidelines.

• Post bronchodilator (following inhalation of salbutamol) forced expired volume in one second(FEV1)/forced vital capacity(FVC) ratio =0.70.

• Willing and able to provide written informed consent.

• Willing and able to attend all study visits and adhere to all study assessments and procedures.

Exclusion Criteria:

• Severe comorbidities including unstable cardiac or pulmonary disease or any other medical conditions including unstable ischemic heart disease,unstable cardiac arrhythmia or heart failure,life threatening arrhythmias,etc.

• Recent history of chronic obstructive pulmonary disease exacerbation requiring hospitalization or need for increased treatments for chronic obstructive pulmonary disease within 6 weeks.

Related Conditions & MeSH terms

• Chronic Disease
• Exercise
• Lung Diseases
• Lung Diseases, Obstructive
• Lung Function Decreased
• Pulmonary Disease, Chronic Obstructive
• Quality of Life
• Respiratory Insufficiency

Intervention

Drug:
• Budesonide and formoterol bid
At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months` treatment.

Locations

Country	Name	City	State
China	Zhujiang Hospital of Southern Medical University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes of forced expired volume in one second(FEV1) after 6-min walk test compared with resting state	Forced expired volume in one second(FEV1) is measured by Jaeger MasterScreen Pulmonary Function Test System before and after 6-min walk test.	At resting state and after 6-min walk test
Secondary	Changes of inspiratory capacity(IC) after 6-min walk test compared with resting state	Inspiratory capacity(IC) is measured by Jaeger MasterScreen Pulmonary Function Test System before and after 6-min walk test.	At resting state and after 6-min walk test
Secondary	Changes of blood oxygen saturation after 6-min walk test compared with resting state	Blood oxygen saturation is measured before and after 6-min walk test.	At resting state and after 6-min walk test
Secondary	Changes of pulse after 6-min walk test compared with resting state	Pulse is measured before and after 6-min walk test.	At resting state and after 6-min walk test
Secondary	Changes of forced expired volume in one second(FEV1) after 3 months` treatment compared with baseline	At baseline,forced expired volume in one second(FEV1) is measured.After 3 months`s treatment of budesonide and formoterol,FEV1 will be measured again.	Change from baseline to 3 months
Secondary	Changes of inspiratory capacity(IC) after 3 months` treatment compared with baseline	At baseline,inspiratory capacity(IC) is measured.After 3 months`s treatment of budesonide and formoterol,IC will be measured again.	Change from baseline to 3 months
Secondary	Changes of diffusion function after 3 months` treatment compared with baseline	At baseline,diffusion function is measured.After 3 months`s treatment of budesonide and formoterol,diffusion function will be measured again.	Change from baseline to 3 months
Secondary	Changes of impulse forced oscillometry parameters after 3 months` treatment compared with baseline	At baseline,impulse forced oscillometry parameters are measured.After 3 months`s treatment of budesonide and formoterol,impulse forced oscillometry parameters will be measured again.	Change from baseline to 3 months
Secondary	Changes of modified Medical Research Council dyspnoea scale(mMRC) scores after 3 months` treatment compared with baseline	At baseline,quality of life is assessed by modified Medical Research Council dyspnoea scale(mMRC).After 3 months`s treatment of budesonide and formoterol,the mMRC scores will be measured again.	Change from baseline to 3 months
Secondary	Changes of St George's Respiratory Questionnaire(SGRQ) scores after 3 months` treatment compared with baseline	At baseline,quality of life is assessed by St George's Respiratory Questionnaire(SGRQ).After 3 months`s treatment of budesonide and formoterol,the SGRQ scores will be measured again.	Change from baseline to 3 months
Secondary	Changes of clinical chronic obstructive pulmonary questionnaire(CCQ) scores after 3 months` treatment compared with baseline	At baseline,quality of life is assessed by clinical chronic obstructive pulmonary disease questionnaire(CCQ).After 3 months`s treatment of budesonide and formoterol,the scores will be measured again.	Change from baseline to 3 months
Secondary	Changes of chronic obstructive pulmonary disease assessment test(CAT) scores after 3 months` treatment compared with baseline	At baseline,quality of life is assessed by chronic obstructive pulmonary disease assessment test(CAT).After 3 months`s treatment of budesonide and formoterol,the test will be performed again.	Change from baseline to 3 months
Secondary	The distance and steps of 6-min walk test	Both the the distance and steps are measured	Change from baseline to 3 months